Invention Application
- Patent Title: RECOMBINANT HOST CELL WITH ALTERED MEMBRANE LIPID COMPOSITION
-
Application No.: US16499072Application Date: 2018-03-28
-
Publication No.: US20210301313A1Publication Date: 2021-09-30
- Inventor: Karlheinz Grillitsch , Guenther Daum , Andreas Grutsch
- Applicant: Boehringer Ingelheim RCV GmbH & Co KG , SANDOZ AG , Validogen GmbH , BIOMIN HOLDING GMBH , Lonza Ltd
- Applicant Address: AT Wien; CH Basel; AT Grambach; AT Herzogenburg; CH Visp
- Assignee: Boehringer Ingelheim RCV GmbH & Co KG,SANDOZ AG,Validogen GmbH,BIOMIN HOLDING GMBH,Lonza Ltd
- Current Assignee: Boehringer Ingelheim RCV GmbH & Co KG,SANDOZ AG,Validogen GmbH,BIOMIN HOLDING GMBH,Lonza Ltd
- Current Assignee Address: AT Wien; CH Basel; AT Grambach; AT Herzogenburg; CH Visp
- Priority: EP17163588.1 20170329
- International Application: PCT/EP2018/057853 WO 20180328
- Main IPC: C12P21/02
- IPC: C12P21/02 ; C12N15/67 ; C12N15/81 ; C07K16/00

Abstract:
The present invention is in the field of recombinant biotechnology, in particular in the field of protein expression. The invention generally relates to a method of expressing a protein of interest (POI) from a host cell. The invention relates particularly to improving a host cell's capacity to express and/or secrete a protein of interest and use of the host cell for protein expression. The invention also relates to cell culture technology, and more specifically to culturing cells to produce desired molecules for medical purposes or food products.
Public/Granted literature
- US11479798B2 Recombinant host cell with altered membrane lipid composition Public/Granted day:2022-10-25
Information query